Earnings Call
Apr 29, 2026
Q1 FY2026
EPS Estimate
8.91
EPS Actual
9.47
Post-Earnings Close
$686.36
Earnings Reaction
-6.2%
Regeneron opened 2026 with broad-based commercial momentum and a pipeline that is beginning to crystallize around several potentially large franchises. Total revenues rose 19% year-over-year to $3.6 billion, and non-GAAP EPS grew 15% to $9.47, comfortably ahead of the $8.91 consensus estimate. The headline driver remains DUPIXENT, which posted $4.9 billion in global net sales, 31% growth on a constant-currency basis, and is now tracking toward annualized global sales approaching $20 billion. With more than 1.4 million patients on therapy and recent label expansions into allergic fungal rhinosinusitis and pediatric chronic spontaneous urticaria, the asset continues to deepen its penetration across type 2 inflammatory diseases well before any meaningful IP cliff. Management was deliberately vague on patent timelines, noting the breadth of composition, formulation, and use patents, and signaled openness to life cycle collaboration with Sanofi under incoming CEO Belen Garijo.
Report generated on May 1, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full REGN analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.